FLT3-ITD induces ara-C resistance in myeloid leukemic cells through the repression of the ENT1 expression

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 1001-1006

  Jin, Guilan ^a   Matsushita, Hiromichi ^a   Asai, Satomi ^a   Tsukamoto, Hideo ^a   Ono, Ryoichi ^b   Nosaka, Tetsuya ^b   Yahata, Takashi ^a   Takahashi, Shinichiro ^c   Miyachi, Hayato ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Ara C resistance; ENT1; FLT3 ITD; HIF 1 ; Myeloid leukemia

Indexed keywords

CD135 ANTIGEN; CISPLATIN; CYTARABINE; DOXORUBICIN; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; ETOPOSIDE; FMS LIKE TYROSINE KINASE 3 INTERNAL TANDEM DUPLICATION PROTEIN; FOLIC ACID ANTAGONIST; HYPOXIA INDUCIBLE FACTOR 1ALPHA; METHOTREXATE; PYRIMIDINE DERIVATIVE; TUMOR PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG UPTAKE; GENE INDUCTION; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; MYELOID LEUKEMIA; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; TANDEM REPEAT; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CYTARABINE; DOWN-REGULATION; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEUKEMIA, MYELOID, ACUTE; PROMOTER REGIONS, GENETIC;

ARA; MURINAE;

EID: 70449720501     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.094     Document Type: Article

References (32)

1. Kelly L.M., and Gilliland D.G. Genetics of myeloid leukemias. Annu. Rev. Genom. Hum. Genet. 3 (2002) 179-198
2. Small D. FLT3 mutations: biology and treatment. Hematol. Am. Soc. Hematol. Educ. Program (2006) 178-184
3. Kiyoi H., and Naoe T. Biology clinical relevance and molecularly targeted therapy in acute leukemia with FLT3 mutation. Int. J. Hematol. 83 (2006) 301-308
4. Stirewalt D.L., and Radich J.P. The role of FLT3 in haematopoietic malignancies. Nat. Rev. Cancer 3 (2003) 650-665
5. Reilly J.T. Class III receptor tyrosine kinases: role in leukaemogenesis. Br. J. Haematol. 116 (2002) 744-757
6. Kelly L.M., Liu Q., Kutok J.L., Williams I.R., Boulton C.L., and Gilliland D.G. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99 (2002) 310-318
7. Renneville A., Boissel N., Gachard N., Naguib D., Bastard C., de Botton S., Nibourel O., Pautas C., Reman O., Thomas X., Gardin C., Terré C., Castaigne S., Preudhomme C., and Dombret H. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 113 (2009) 5090-5093
8. Schlenk R.F., Döhner K., Krauter J., Fröhling S., Corbacioglu A., Bullinger L., Habdank M., Späth D., Morgan M., Benner A., Schlegelberger B., Heil G., Ganser A., Döhner H., and German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N. Engl. J. Med. 358 (2008) 1909-1918
9. Kruh G.D. Introduction to resistance to anticancer agents. Oncogene 22 (2003) 7262-7264
10. Matsushita H., Nakajima H., Nakamura Y., Tsukamoto H., Tanaka Y., Jin G., Yabe M., Asai S., Ono R., Nosaka T., Sugita K., Morimoto A., Hayashi Y., Hotta T., Ando K., and Miyachi H. C/EBPalpha and C/EBPepsilon induce the monocytic differentiation of myelomonocytic cells with the MLL-chimeric fusion gene. Oncogene 27 (2008) 6749-6760
11. Ono R., Nakajima H., Ozaki K., Kumagai H., Kawashima T., Taki T., Kitamura T., Hayashi Y., and Nosaka T. Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J. Clin. Invest. 115 (2005) 919-929
12. Miyachi H., Ma L., Takemura Y., Kobayashi H., Hirahara I., Sonehara H., and Ando Y. Microsatellite instability and clonal heterogeneity of MDR1 messenger RNA expression in trimetrexate-resistant human leukemia MOLT-3 cells developed in thymidine. Int. J. Cancer 82 (1999) 63-69
13. Fröhling S., Schlenk R.F., Breitruck J., Benner A., Kreitmeier S., Tobis K., Döhner H., and Döhner K. Prognostic significance of activating FLT3 mutations in younger adults (16-60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100 (2002) 4372-4380
14. Cai J., Damaraju V.L., Groulx N., Mowles D., Peng Y., Robins M.J., Cass C.E., and Gros P. Two distinct molecular mechanisms underlying cytarabine resistance in human leukemic cells. Cancer Res. 68 (2008) 2349-2357
15. Nakanishi T., Karp J.E., Tan M., Doyle L.A., Peters T., Yang W., Wei D., and Ross D.D. Quantitative analysis of breast cancer resistance protein and cellular resistance to flavopiridol in acute leukemia patients. Clin. Cancer Res. 9 (2003) 3320-3328
16. Zimmerman E.I., Huang M., Leisewitz A.V., Wang Y., Yang J., and Graves L.M. Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett. 583 (2009) 425-429
17. Takagaki K., Katsuma S., Kaminishi Y., Horio T., Nakagawa S., Tanaka T., Ohgi T., and Yano J. Gene-expression profiling reveals down-regulation of equilibrative nucleoside transporter 1 (ENT1) in Ara-C-resistant CCRF-CEM-derived cells. J. Biochem. 136 (2004) 733-740
18. Song J.H., Kim S.H., Kweon S.H., Lee T.H., Kim H.J., Kim H.J., and Kim T.S. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int. J. Oncol. 34 (2009) 1165-1171
19. Yamauchi T., Negoro E., Kishi S., Takagi K., Yoshida A., Urasaki Y., Iwasaki H., and Ueda T. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5′-nucleotidase II expression ratio in primary acute myeloid leukemia cells. Biochem. Pharmacol. 77 (2009) 1780-1786
20. Yusa K., Oh-hara T., Tsukahara S., and Tsuruo T. Human immunodeficiency virus type 1 induces 1-beta-d-arabinofuranosylcytosine resistance in human H9 cell line. J. Biol. Chem. 267 (1992) 16848-16850
21. Steuart C.D., and Burke P.J. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat. New Biol. 233 (1971) 109-110
22. Mahadevan D., and List A.F. Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. Blood 104 (2004) 1940-1951
23. Eltzschig H.K., Abdulla P., Hoffman E., Hamilton K.E., Daniels D., Schönfeld C., Löffler M., Reyes G., Duszenko M., Karhausen J., Robinson A., Westerman K.A., Coe I.R., and Colgan S.P. HIF-1-dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia. J. Exp. Med. 202 (2005) 1493-1505
24. Brahimi-Horn M.C., and Pouysségur J. HIF at a glance. J. Cell Sci. 122 (2009) 1055-1057
25. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3 (2003) 721-732
26. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., Patil S.R., Davey F.R., Berg D.T., Schiffer C.A., Arthur D.C., and Mayer R.J. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 58 (1998) 4173-4179
27. Tallman M.S., Gilliland D.G., and Rowe J.M. Drug therapy for acute myeloid leukemia. Blood 106 (2005) 1154-1163
28. Kim K.T., Levis M., and Small D. Constitutively activated FLT3 phosphorylates BAD partially through pim-1. Br. J. Haematol. 134 (2006) 500-509
29. Nosaka T., and Kitamura T. Pim-1 expression is sufficient to induce cytokine independence in murine hematopoietic cells, but is dispensable for BCR-ABL-mediated transformation. Exp. Hematol. 30 (2002) 697-702
30. Seedhouse C.H., Hunter H.M., Lloyd-Lewis B., Massip A.M., Pallis M., Carter G.I., Grundy M., Shang S., and Russell N.H. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 20 (2006) 2130-2136
31. Kohno K., Uchiumi T., Niina I., Wakasugi T., Igarashi T., Momii Y., Yoshida T., Matsuo K., Miyamoto N., and Izumi H. Transcription factors and drug resistance. Eur. J. Cancer 41 (2005) 2577-2586
32. Oveland E., Gjertsen B.T., Wergeland L., Selheim F., Fladmark K.E., and Hovland R. Ligand-induced Flt3-downregulation modulates cell death associated proteins and enhances chemosensitivity to idarubicin in THP-1 acute myeloid leukemia cells. Leuk. Res. 33 (2009) 276-287